BioSpace News Archive

A new study published in the journal World Neurosurgery demonstrated that automated infrared pupillometry can improve triage and expedite treatment for patients with traumatic brain injuries.

Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr. Klatzmann of Sorbonne University on Wednesday, November 4, 2020 at 4:15 p.m. EST . The event will follow Wednesday’s virtual release by ACR of the poster presentation of data

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, wishes to advise that its 2020 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held today, October 29, 2020 at 1.00 p.m. Pacific Time

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced its financial results for the 2020 fiscal year ended July 31, 2020.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of $24.00 per share.

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of $16.00 per share.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it will present new data from the previously announced Phase 2 studies of ARQ-151

HEXO Corp. (TSX: HEXO; NYSE: HEXO) (“HEXO” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended July 31, 2020.

Burning Rock Biotech Limited announced that analytical validation data of its fully-automated NGS library preparation platform, Magnis BR, will be presented at the Association for Molecular Pathology 2020 annual meeting, in a platform presentation on Thursday, November 19, 2020.